Association of an activated clotting time < or =250 seconds with adverse event rates after percutaneous coronary intervention using tirofiban and heparin (a TACTICS-TIMI 18 substudy)

Am J Cardiol. 2003 Apr 15;91(8):976-8, A4. doi: 10.1016/s0002-9149(03)00117-6.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angioplasty, Balloon, Coronary*
  • Blood Coagulation Tests / standards*
  • Coronary Disease / therapy
  • Female
  • Fibrinolytic Agents / administration & dosage
  • Hemorrhage / chemically induced*
  • Heparin / administration & dosage*
  • Humans
  • Male
  • Middle Aged
  • Tirofiban
  • Tyrosine / administration & dosage*
  • Tyrosine / analogs & derivatives

Substances

  • Fibrinolytic Agents
  • Tyrosine
  • Heparin
  • Tirofiban